Global Plasmid DNA Manufacturing Market Size study & Forecast, by Grade (R&D Grade, GMP Grade), by Development (Pre-Clinical Therapeutics, Clinical Therapeutics, Marketed Therapeutics), by Application (DNA Vaccines, Cell & Gene Therapy, Immunotherapy, Oth

Global Plasmid DNA Manufacturing Market Size study & Forecast, by Grade (R&D Grade, GMP Grade), by Development (Pre-Clinical Therapeutics, Clinical Therapeutics, Marketed Therapeutics), by Application (DNA Vaccines, Cell & Gene Therapy, Immunotherapy, Others), by Disease (Infectious Disease, Cancer, Genetic Disorder) and Regional Analysis, 2022-2029

Global Plasmid DNA Manufacturing Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Plasmid DNA manufacturing is a process of producing plasmid DNA that is directly used as a therapeutic agent such as in gene therapy or vaccine generation antigens. Factors such as the flourishing growth of the healthcare industry, the rising number of patients opting for gene therapy, and the increasing demand for plasmid DNA in various medical therapies are upsurging the market demand across the world.

According to Statista, in 2019, the global cancer gene therapy market was estimated to value around USD 560 million, which is anticipated to grow and is likely to reach USD 16,500 million by the year 2030. Therefore, the increasing demand for gene therapy is exhibiting a positive influence on the growth of the Plasmid DNA Manufacturing Market. In addition, a robust pipeline for gene therapies, as well as the increasing number of strategies by the key market players are offering various lucrative opportunities for market growth in the forecasting years. However, the imposition of a stringent regulatory framework and ethical challenges associated with gene therapy are hindering stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Plasmid DNA Manufacturing Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the space in terms of revenue, owing to the rising emphasis on the establishing Recombinant DNA Advisory Committee, along with the growing investment the R&D activities. Whereas, Asia Pacific is expected to grow significantly during the forecast period. Factors such as
rising inclination toward the development and marketing of stem cells, untapped opportunities, as well as growing incidences of target diseases are burgeoning the market growth in the forecasting years.

Major market players included in this report are:
Charles River Laboratories
VGXI, Inc.
Aldevron
Kaneka Corp.
Nature Technology
Cell and Gene Therapy Catapult
Eurofins Genomics
Lonza
Luminous BioSciences, LLC
Akron Biotech
Recent Developments in the Market:
in July 2021, Thermo Fisher announced the establishment of its current Good Manufacturing Practice (cGMP) facility in Carlsbad, California, with the objective of boosting its clinical and business capabilities for the synthesis of pDNA for cells and gene-based therapies.
In June 2021, Biotage announced the introduction of Biotage PhyPrep- a new automated solution for plasmid DNA purification. This new automated solution for plasmid DNA purification saves lab technicians’ time by eradicating the requirement to perform repetitive, manual work and also helps in producing supercoiled, endotoxin-free, transfection-grade pDNA.
Global Plasmid DNA Manufacturing Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered

Grade, Development, Application, Disease, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Grade:
R&D Grade
GMP Grade
By Development:
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
By Application:
DNA Vaccines
Cell & Gene Therapy
Immunotherapy
Others
By Disease:
Infectious Disease
Cancer
Genetic Disorder

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the WorldCompanies Mentioned

Charles River Laboratories
VGXI, Inc.
Aldevron
Kaneka Corp.
Nature Technology
Cell and Gene Therapy Catapult
Eurofins Genomics
Lonza
Luminous BioSciences, LLC
Akron Biotech

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.